STING1 and neoplasm: The effective use of STING therapy in combination with PD-1/PD-L1 inhibition in the treatment of cancer is limited by numerous pharmacological, immunological, and tumor microenvironment challenges, although novel drug delivery and combination strategies are being developed to overcome existing barriers and enhance the efficacy and safety of therapies.